Bio-Techne Corporation (TECH)
Automate Your Wheel Strategy on TECH
With Tiblio's Option Bot, you can configure your own wheel strategy including TECH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TECH
- Rev/Share 7.681
- Book/Share 12.8233
- PB 3.7908
- Debt/Equity 0.2099
- CurrentRatio 3.707
- ROIC 0.0666
- MktCap 7620443870.0
- FreeCF/Share 1.4028
- PFCF 34.5199
- PE 58.1004
- Debt/Assets 0.1602
- DivYield 0.0066
- ROE 0.0634
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TECH | Wells Fargo | -- | Overweight | -- | $59 | May 30, 2025 |
| Downgrade | TECH | KeyBanc Capital Markets | Overweight | Sector Weight | -- | -- | April 9, 2025 |
| Initiation | TECH | Evercore ISI | -- | Outperform | -- | $75 | March 18, 2025 |
| Downgrade | TECH | Robert W. Baird | Outperform | Neutral | $88 | $68 | Feb. 19, 2025 |
News
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bio-Techne's TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company's efforts to expand its portfolio, as well as enter adjacent markets.
Read More
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.
Read More
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Read More
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.
Read More
Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation (NASDAQ:TECH ) Q3 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President & Chief Executive Officer Jim Hippel - Executive Vice President & Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Dan Leonard - UBS Matt Larew - William Blair Daniel Markowitz - Evercore Dan Arias - Stifel Thomas DeBourcy - Nephron Research Patrick Donnelly - Citi Sung Ji Nam - Scotiabank Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter of Fiscal Year 2025. At …
Read More
Techne (TECH) Reports Q3 Earnings: What Key Metrics Have to Say
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Is the Options Market Predicting a Spike in BioTechne Stock?
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to TECH stock based on the movements in the options market lately.
Read More
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Techne (TECH) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.48 per share a year ago.
Read More
Bio-Techne exceeds profit expectations, announces new share buyback plan
Published: May 07, 2025 by: Reuters
Sentiment: Positive
Bio-Techne on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other products for research and said it is launching a new share buyback program.
Read More
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.
Read More
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025.
Read More
U.S. politician makes suspicious biotech stock bet
Published: May 05, 2025 by: Finbold
Sentiment: Negative
Finbold's congressional trading radar has recently picked up a suspicious stock bet made by Maryland congresswoman April McClain Delaney involving a low-profile biotech stock.
Read More
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
Read More
Bio-Techne Opens New Customer Experience Centre in Germany
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.
Read More
Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy. The new Customer Experience Centre is scheduled to open in summer 2026 and will feature a state-of-the-art Demonstration Laboratory hosting Bio-Techne's full instrument portfolio, including: The recently launched Leo™ System, powered by Simple Western™ Technology, which offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows …
Read More
Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA.
Read More
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss.
Read More
Bio-Techne to Present at Investor Conferences
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , Feb. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 45th Annual Health Care Conference March 4, 2025 2:30 PM EST Leerink Partners Global Healthcare Conference March 11, 2025 11:20 AM EDT Barclays 27th Annual Global Healthcare Conference March 12, 2025 10:00 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research …
Read More
EXEL or TECH: Which Is the Better Value Stock Right Now?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
Read More
Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with industry-leading sensitivity and specificity, the Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species.
Read More
Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies. The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types.
Read More
About Bio-Techne Corporation (TECH)
- IPO Date 1989-02-09
- Website https://www.bio-techne.com
- Industry Biotechnology
- CEO Mr. Kim Kelderman
- Employees 3100